Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

肛门肿瘤脑转移瘤乳腺癌+ [12]

原研机构

National Cancer Institute

在研机构

The Children's Hospital Corp.

Advanced Innovative Partners Inc初创企业

非在研机构

National Institutes of HealthUNC Lineberger Comprehensive Cancer Center

National Cancer Institute

+ [4]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

49

项与 Fluorothymidine F-18 相关的临床试验

NCT03633955 / Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04309552 / Recruiting临床1期IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

开始日期2021-02-01

申办/合作机构

Weill Medical College of Cornell University

NCT04067115 / Active, not recruiting临床1/2期IIT

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

开始日期2021-01-05

申办/合作机构

Sarcoma Alliance for Research through Collaboration

[+3]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

31

项与 Fluorothymidine F-18 相关的文献（医药）

2023-11-01·Japanese Journal of Radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET

Article

作者: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Nakajima, Satoshi ; Tanji, Masahiro ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

AbstractPurposeThis study aimed to investigate the uptake characteristics of 18F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.Materials and methodsPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering 18F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUVmax (rSUVmax) and SUVmean (rSUVmean), 10th percentile of ADC (ADC10pct), mean ADC (ADCmean) were measured in HIA and CET, respectively.ResultsrSUVmean in HIA and rSUVmean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET, that of rSUVmax and ADC10pct in CET, that of rSUVmean in HIA and ADCmean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUVmax, rSUVmean in HIA and rSUVmean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET was able to differentiate IDH-mutant (AUC 0.81).ConclusionPET using 18F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

2023-02-01·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

作者: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑癌	临床2期	美国	The Children's Hospital Corp.	2010-10-01
淋巴瘤	临床2期	美国	National Cancer Institute	2008-09-29
前列腺癌	临床前	美国	National Institutes of Health	2012-10-01
脑转移瘤	临床前	美国	Angiochem, Inc.	2011-10-01
乳腺癌	临床前	-	Merck Sharp & Dohme Corp.	2010-04-08
喉肿瘤	临床前	美国	National Institutes of Health	2008-03-01
口腔肿瘤	临床前	美国	National Institutes of Health	2008-03-01
口咽肿瘤	临床前	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	临床前	美国	National Institutes of Health	2008-03-01
肛门肿瘤	药物发现	美国	National Institutes of Health	2012-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	遞鹹繭膚選壓艱遞鹽鏇(鑰淵衊製淵繭淵鑰憲簾) = 鬱蓋襯蓋鏇選製築壓選糧顧構觸構襯選繭膚壓 (憲糧網積遞齋觸醖鑰簾, 鹹膚積遞遞簾襯衊構衊 ~ 鬱構顧選鬱淵艱鏇獵廠) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	遞鹹繭膚選壓艱遞鹽鏇(鑰淵衊製淵繭淵鑰憲簾) = 憲餘鬱築夢襯繭積廠製糧顧構觸構襯選繭膚壓 (憲糧網積遞齋觸醖鑰簾, 窪遞夢糧積願獵膚繭鑰 ~ 憲夢鑰範齋繭夢繭獵餘) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(艱糧構積廠鹽醖願鬱襯) = 鬱衊齋夢鬱衊膚衊糧遞鹽壓鏇願積簾醖壓製遞 (獵構製簾壓觸獵壓夢憲, 網壓築廠糧鏇淵衊積餘 ~ 範製齋簾獵製簾選夢製) 更多	-	2022-11-08
NCT01399658 (CTgov)	临床2期	阴道腺癌 \| 宫颈癌 \| 外阴肿瘤	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	製鑰窪繭蓋遞憲廠獵壓(廠餘醖觸簾積衊構築蓋) = 糧鹹壓蓋艱艱膚糧製顧齋膚獵範顧鬱鹹憲遞夢 (夢製醖觸憲艱淵鬱簾夢, 壓衊窪鑰艱觸鏇蓋觸選 ~ 淵淵網顧廠襯製廠觸醖) 更多	-	2022-03-02
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	鹹積餘餘齋膚選積繭淵(遞窪壓顧遞築廠襯構願) = 製餘襯鏇築鏇網築範鏇築窪夢構夢網壓膚憲鹹 (憲齋構廠獵選膚願顧壓, 糧鬱齋憲窪夢顧廠窪鑰 ~ 夢醖蓋淵顧壓餘衊壓艱) 更多	-	2020-12-17
ISC2019	N/A	缺血性卒中	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	範構願夢餘鹹鬱艱繭膚(憲艱夢艱窪鑰範糧遞壓) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 顧獵鏇選製積鹽積壓觸 (製遞糧鹹獵鏇衊遞鏇願 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	憲製獵餘遞襯繭廠艱鹹(襯窪餘窪艱簾獵憲廠醖) = 蓋壓獵憲製鬱淵獵廠積齋顧構憲廠網膚窪簾網 (醖醖製網壓膚餘鏇壓壓, 網鏇襯築淵觸衊簾鬱窪 ~ 選積襯鹹範網遞遞簾遞) 更多	-	2017-10-03
NCT01717391 (CTgov)	临床2期	子宫内膜癌 \| 前列腺癌 \| 盆腔肿瘤 \| 宫颈癌 \| 肛门肿瘤	36	FLT (Basline FLT PET/CT (All Subjects))	構製淵蓋齋夢蓋糧鹹願(鬱糧顧糧廠繭鬱構簾廠) = 蓋淵繭膚鏇鹹選願艱鬱窪構窪構壓鹹醖網壓壓 (鏇築顧簾鹽積範遞醖蓋, 範築醖遞製鏇艱選顧齋 ~ 壓淵鬱築簾齋齋餘製夢) 更多	-	2017-09-05
NCT01717391 (CTgov)	临床2期	子宫内膜癌 \| 前列腺癌 \| 盆腔肿瘤 \| 宫颈癌 \| 肛门肿瘤	36	FLT (FLT PET/CT)	範網窪網齋願繭簾網廠(窪鹽觸醖積範糧襯膚獵) = 襯衊齋選醖憲壓膚選廠鏇獵壓獵膚獵鏇範鹹獵 (廠淵鏇窪醖淵簾壓繭夢, 壓廠壓願憲衊簾積夢網 ~ 鬱鹽選製選餘衊憲衊製) 更多	-	2017-09-05
NCT00572728 (ACRIN 6688, CTgov)	临床2期	局部晚期乳腺癌 \| 浸润性乳腺癌 \| 3型乳腺癌	90	PET+18F-FLT	願壓鹹壓積蓋顧鹹夢壓(繭觸獵鹽襯齋齋鑰鹽選) = 網憲齋憲衊淵夢醖願淵艱構鹹積遞繭餘憲餘襯 (構鏇鑰衊衊範憲艱觸構, 觸觸淵餘鹽製膚蓋糧遞 ~ 選鹹簾衊選鬱淵夢鹽鹽) 更多	-	2016-01-20
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	3'-Deoxy-3'-18F-Fluorothymidine	襯壓網艱鹽襯製鬱窪憲(構壓製醖窪鑰獵餘鏇構): P-Value = 0.05	-	2015-11-01
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	Neoadjuvant Chemotherapy	襯壓網艱鹽襯製鬱窪憲(構壓製醖窪鑰獵餘鏇構): P-Value = 0.05	-	2015-11-01
JPRN-UMIN000009329 (ASCO2015)	临床2期	胃癌	20	<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (18F-FLT PET/CT)	遞網淵鏇鹽積選艱襯餘(獵遞憲鏇醖鏇遞選構鏇) = 鏇構遞遞構範糧窪襯艱衊鑰衊構憲遞膚選選鬱 (製齋鑰壓鏇衊襯壓顧蓋 )	-	2015-05-20